Comparative Pharmacology
Head-to-head clinical analysis: MELAMISA versus ROWASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELAMISA versus ROWASA.
MELAMISA vs ROWASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meloxicam selectively inhibits cyclooxygenase-2 (COX-2), reducing the synthesis of prostaglandins involved in inflammation, pain, and fever, while sparing COX-1 activity at therapeutic doses.
5-aminosalicylic acid (5-ASA) inhibits prostaglandin and leukotriene synthesis, reduces neutrophil chemotaxis, and scavenges reactive oxygen species, thereby exerting anti-inflammatory effects on the colonic mucosa.
100 mg orally twice daily for 5 days; take with food.
Rectal suspension enema: 4 g (60 mL) once daily at bedtime, retained for at least 8 hours. Rectal suppository: 500 mg twice daily (one in the morning and one at bedtime).
None Documented
None Documented
Terminal elimination half-life is 6.5–9.8 hours in adults with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life of mesalamine (5-ASA) is approximately 0.5-2 hours; N-acetyl-5-ASA half-life is 5-10 hours. Rectal administration prolongs local retention without altering systemic half-life.
Renal (approximately 50% as unchanged drug and metabolites), biliary/fecal (approximately 30%), with minor pulmonary elimination. Total clearance is about 1.2 mL/min/kg.
Renal: approximately 78% (primarily N-acetyl-5-ASA and unchanged 5-ASA). Fecal: approximately 20% (unabsorbed drug). Biliary: negligible (<1%).
Category C
Category C
Aminosalicylate
Aminosalicylate